| abstract |
The present invention suppresses premature elution and absorption even when orally administered, and the risk of unexpected side effects due to a temporary increase in blood concentration is relatively low. The following (1) to (4) Aqueous suspension type pharmaceutical preparation containing (1) (3aR, 4S, 7R, 7aS) -2-{(1R, 2R) -2- [4- (1,2-benzoisothiazole-3-yl) piperazine-1-ylmethyl] cyclohexylmethyl} hexahydro -4,7-methano-2H-isoindole-1,3-dione, a pharmaceutically acceptable acid addition salt thereof or a mixture thereof, (2) Xanthan gum (3) Dispersant and (4) Water are provided. |